KPV Dosage Guide 2026: The Research vs Reported Use

The calculator

Five inputs, three outputs: a vial size, a water volume, a syringe scale, a barrel size and a mass go in; the concentration, the volume and the barrel reading come out.

Is there a KPV dose behind the posted protocols?

The honest version of the answer is short: the two columns below do not disagree about a number. One of them has no numbers in it at all.

A tripeptide in a mouse's water bottle and a vial of powder on a kitchen counter are not the same experiment at two scales.

What the left column is actually evidence about: that KPV reduces measured inflammation in specific animal models and specific cell lines, by a mechanism that is not the one its hormone parent uses. Carrying that across to a milligram figure for a person needs a bridge we could not find in any record we searched, and neither could the agency: no pharmacokinetic or toxicokinetic study of either form of the substance, and no human exposure data by any route beyond one case report of an adverse reaction that names no quantity at all.

What does a 0.1% KPV cream actually hold?

The percentage as a quantity: 0.1% by weight is one part in a thousand, so a gram of a 0.1% cream holds 1mg of KPV and a 30-gram tube holds 30mg. That arithmetic is the entire content of the figure, and it is the only strength in FDA's compounding file for this peptide.

Why FDA could not go further than that: the nomination never said what vehicle the cream or gel would use. For a topical product, solubility and particle size are what keep potency even through the tube, and without a formulation the agency wrote that it could not evaluate how those characteristics would affect the finished product.

The solubility figure sitting underneath it: FDA reports KPV free base as soluble in water up to 0.70mg per mL, and KPV acetate as dissolving at 5mg per mL. Both figures are cited in the briefing document to seller-published material, which is the best evidence the agency could find, and they sit a factor of about seven apart. Only the first is written as an upper limit. The acetate figure is a concentration a seller reports going into solution, not a point the agency says it stops.

What that gap does to a vial of powder: at 0.70mg per mL, the free base in a 5mg vial would need more than 7mL of water before all of it was in solution, and a 2mg vial would need close to 3mL. At the acetate's reported 5mg per mL, the same 5mg goes into 1mL. Those are two different liquids with the same three letters printed on the label.

Whether a certificate settles which one is in the vial: often it cannot. FDA records that the same CAS number, 67727-97-3, is used for the free base and for the acetate in most public references, and that the certificate submitted with the KPV nomination named one substance in its title and a different one by molecular formula. Our note on how to read a peptide certificate of analysis covers what a document like that can and cannot establish.

And a purity line does not close the gap either: the agency ran its own literature searches for certificates covering the free base and found that most contain only a purity testing result, with no impurity limits acting as a control, no information on the peptide's tendency to aggregate, and nothing showing whether the microbiological testing a topical product requires had been done at all. That is the same shortfall we set out in what an HPLC purity figure leaves out, arrived at independently by a regulator reading the same documents.

The storage numbers, and where they come from: FDA reports lyophilized KPV free base as stable up to 3 years at minus 20 degrees Celsius, up to 2 years at 4 degrees, and up to 3 months at 15 degrees, with the reconstituted solution reported at 6 months, 1 month and 1 week for minus 80, minus 2 and 10 degrees. Those figures are quoted in the briefing document from a seller's certificate of analysis for KPV 2mg, not from a stability study, and what freeze-drying does and does not preserve is worth reading alongside them.

How does the units math work on a 2mg or 5mg vial?

General arithmetic, no dose attached: what follows describes powder and water, not a person. The 2mg and 5mg amounts are the two quantities FDA's footnotes name; the container and the water volumes below are worked examples, not figures out of any document. Nothing in this section is a recommendation, and none of it says what belongs in a syringe.

The 5mg vial in 2mL: a 5mg vial reconstituted with 2mL of bacteriostatic water holds 2.5mg per mL, the same thing as 2,500mcg per mL.

Against a U-100 barrel: that scale is printed 100 units to the milliliter, so one unit is 0.01mL, carrying 25mcg in this mix. On that reading, 500mcg lands on 20 units.

The same vial in 1mL instead: half the water, so the concentration doubles to 5mg per mL and every unit now carries 50mcg. The same 500mcg reads as 10 units, half of what it read before.

Down to the 2mg vial: 2mg in 1mL is 2mg per mL, each unit is worth 20mcg, and 500mcg reads as 25 units.

Reversed, a bare unit count stops being a quantity: 20 units of the first mix is 500mcg, 20 units of the second is 1,000mcg, and the barrel looks identical either way.

One row in that table has a chemistry problem the arithmetic cannot see: the middle setup asks 5mg to dissolve in 1mL, which is the concentration reported for the acetate and about seven times the figure FDA gives as the free base's upper limit. The division works. Whether the powder actually goes into solution depends on which of the two substances the vial holds, and the label may not say.

How many units is 500mcg of KPV?

Three mixes, three readings: at 2.5mg per mL, a 5mg vial in 2mL, 500mcg reads as 20 units on a U-100 syringe. At 5mg per mL, the same vial in 1mL, it reads 10 units. At 2mg per mL, a 2mg vial in 1mL, it reads 25 units.

None of those three is the right answer: they are three correct statements about three different liquids that happen to share a label. The number in the question is a mass, the number on the barrel is a volume, and only the concentration connects them.

What's not known yet?

The surveillance databases first, because they are the cheapest place to look: FDA's Office of Surveillance and Epidemiology searched the FAERS adverse event database and the medical literature for KPV through 3 December 2025 and retrieved no reports and no published cases. A search of the Human Foods Complaint System covering 1 January 2004 to 3 December 2025 returned no cases where KPV was administered. The agency states plainly that FAERS reporting is voluntary, that compounders under section 503A generally do not report to it, and that no conclusion about safety can rest on it. That caution is load-bearing here, because the case report in source 14 was published in February 2025, inside the window that literature search covered, and the agency's search did not surface it.

Then the toxicology package, which is a list of absences: FDA identified no acute toxicity studies, no repeat-dose toxicity studies, no genotoxicity studies, no developmental or reproductive toxicity studies and no carcinogenicity studies for either KPV free base or KPV acetate. It also identified no clinical studies and no human exposure data assessing immunogenicity or aggregation, which the agency raises as separate peptide-specific risks that a purity result does not address.

The compounding file, and what it is not: KPV appears on FDA's list of bulk drug substances nominated but withdrawn, on a page the agency dates 22 April 2026, with the entry noting that it has identified no human exposure data by any route and lacks important information about whether the substance would cause harm. That is a procedural listing, not an endorsement and not an approval.

What happened on 23 July 2026: KPV-related bulk drug substances went before FDA's Pharmacy Compounding Advisory Committee under docket FDA-2025-N-6895, with two separate votes on the agenda, one for the free base and one for the acetate. In its briefing document the agency proposed that neither be added to the 503A list, on the grounds that they are not well characterized, that the extent of use in compounding is unknown, and that there is no information on their use in humans from which to draw a conclusion. The committee voted the other way. The Associated Press and NBC News, reporting from the meeting that day, put the tally at 8 in favor, 6 against and 1 abstention across BPC-157, KPV and TB-500. A committee advises; FDA decides by rulemaking.

How thin the record looked from inside the room: during the KPV discussion one committee member, Josh Mailman, said he did not know what he was voting on, described it as "kind of like a black box", and voted no. Another member gave her no vote on KPV a different reason, that the panel was reacting to demand created by a market rather than to evidence. Both accounts come from NBC News reporting of the meeting, because the agency itself has posted an agenda, briefing documents and slides for that day and no result.

Three gaps, and the third is the one under all the others:

• No published study has set out to give KPV to a person and measure what happened, on the searches described above and on FDA's own, so there is no verified dose, schedule, route or duration for it. The one published human exposure we could find is a single case report of an adverse reaction after an oral dose, set out in the safety section below, and it names no amount.
• No pharmacokinetic or toxicokinetic study of either form sits in FDA's record or in the searches we ran, so there is no measured human exposure to work from. In an animal there is now a time course, though of a dye rather than of the peptide: a 2026 oral-delivery paper tracked Cy5-tagged KPV in mice, where an oral dose left colon signal fading by 12 hours and negligible by 24, and an intravenous dose put plasma signal up quickly and back to baseline inside 4 hours. A dye followed by a camera in a mouse is not a concentration measured in a person.
• The name on a vial does not establish which of the two substances is in it, because the free base and the acetate are sold under one common name, share a CAS number in most references, and have no United States Adopted Name to separate them.

Nothing published closes any of the three. The two sources cited at their edges, one case report and one animal time course, mark where the gaps start rather than filling them.

Which puts the first question on the supply chain rather than on the arithmetic: whether the powder is the free base or the acetate, whether it is pure, whether it is sterile, and whether the milligrams on the label are the milligrams in the vial. Every unit count on this page assumes all four, and none of the four is established by anything we could retrieve.

How this page is sourced

Papers and regulator records, read directly: every preclinical figure above came off the cited paper itself, and every regulatory statement came out of the FDA document that carries it, retrieved and read rather than summarized from a secondary account.

Fifteen sources, three of them regulatory: seven preclinical papers with their DOIs and PubMed IDs, one clinician case report collection carrying the only published human exposure we could find, the FDA briefing document for KPV, the meeting record that carries the two votes, FDA's withdrawn-nominations list, a chemical database entry for the molecule, one entry for the news reporting of the committee vote, the four database queries behind this page's own counts, and the university dissertation that carries the underlying skin-permeation experiment. Every one of them is a document or a query a reader can open, run, and hold this page to.

The regulatory lines carry a re-verify date: the compounding status, the committee outcome and the withdrawn-nominations entry were retrieved on 2 August 2026 and carry a 90-day re-verify date, because a rulemaking can change all three.

The absence at the heart of this page was measured, not assumed: a sentence saying no human study exists is a positive claim about a whole literature, so we ran the searches ourselves instead of borrowing the conclusion, printed the query strings above, and gave them their own numbered source entry below so a reader can repeat them rather than trust them. PubMed, searched for KPV in the Title and Abstract fields on 2 August 2026, returned 65 records, and none of them survived its Clinical Trial publication-type filter. ClinicalTrials.gov returned zero studies the same day, both for KPV as a search term and for KPV as an intervention. FDA reports the same absence independently, from its own search of PubMed, Embase and ClinicalTrials.gov, in a memorandum dated 12 May 2026. That is the exact scope of the claim: those databases, those query strings, those dates, and a regulator's search beside them. It is also a method with a demonstrated blind spot, and this page carries the proof of it: the human adverse reaction in source 14 sits inside a paper titled for a different drug, in a journal that neither PubMed nor Europe PMC indexes, so no title-and-abstract query printed above could ever have returned it. We found it by searching the full peptide name across the open web instead.

What a citation has to clear before it ships: the whole standard, including who reads a page before it goes live, is written out on our methodology page, and every correction to a figure on this site is logged there as well as here.

Last reviewed: 3 August 2026.

1. 1

   Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-7. doi:10.1124/jpet.103.051623. PMID 12750433.

2. 2

   Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. doi:10.1002/ibd.20334. PMID 18092346.

3. 3

   Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. doi:10.1053/j.gastro.2007.10.026. PMID 18061177.

4. 4

   Pawar K, Kolli CS, Rangari VK, Babu RJ. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci. 2017;106(7):1814-1820. doi:10.1016/j.xphs.2017.03.017. PMID 28343991.

5. 5

   Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. doi:10.1016/j.ymthe.2016.11.020. PMID 28143741.

6. 6

   Sung J, Ju SY, Park S, Jung WK, Je JY, Lee SJ. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. 2025;95:102837. doi:10.1016/j.tice.2025.102837. PMID 40073467.

7. 7

   U.S. Food and Drug Administration. July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee: FDA Briefing Document for KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate), memorandum dated 12 May 2026, docket FDA-2025-N-6895. Source of the nominated cream/gel 0.1% topical strength, the nominated uses, the physicochemical table, the 0.70mg per mL and 5mg per mL solubility figures, the storage figures, the historical-use and marketing description, the FAERS and Human Foods Complaint System searches, the nonclinical and human-safety absences, and the agency's proposal not to add either substance to the 503A Bulks List. Retrieved 2 August 2026, HTTP 200, 2,152,618 bytes. FDA briefing document, KPV.

8. 8

   U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: meeting page and agenda, and the meeting Questions document setting the two KPV votes, "Should KPV (free base) be placed on the list?" and "Should KPV acetate be placed on the list?". Retrieved 2 August 2026, HTTP 200. Meeting page, meeting questions document.

9. 9

   U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, table headed "Bulk drug substances nominated but withdrawn", KPV entry: "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration." Page content current as of 22 April 2026. Retrieved 2 August 2026, HTTP 200. fda.gov, withdrawn nominations.

10. 10

    News reporting of the committee vote, not an FDA record. NBC News, 23 July 2026, reporting eight yes votes from the new appointees, six no votes and one abstention on BPC-157, KPV and TB-500, and carrying the committee-member quotes used above. Retrieved 2 August 2026, HTTP 200. This response is generated per request and its byte length differs between retrievals, so no size is quoted for it. nbcnews.com. Associated Press, 23 July 2026, reporting 8-6 with one abstention across the votes. apnews.com. Re-checked against the FDA meeting page on 2 August 2026: it publishes an agenda, a roster, briefing documents, the questions document and both days of presentation slides, and no minutes and no tally.

11. 11

    National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, record title "Msh (11-13)", listing molecular formula C16H30N4O4, molecular weight 342.43, CAS 67727-97-3 and, among its 26 synonyms, "Lys-pro-val", "alpha-MSH(11-13)" and "alpha-MSH (11-13) (free acid)". The record title is not the name this page uses for the molecule, which is why it is printed here as the database holds it. Retrieved through the PubChem PUG REST API, 2 August 2026, and re-read 3 August 2026, HTTP 200 both times. PubChem CID 125672.

12. 12

    Our own database searches, not a third-party document: the four queries behind the counts printed in the research section, written out so a reader can re-run them instead of taking them. PubMed, "KPV[Title/Abstract]" returns 65 records and "KPV[Title/Abstract] AND clinical trial[Publication Type]" returns 0, first run 2 August 2026 as this page records and re-run 3 August 2026 through both the E-utilities ESearch endpoint and the web interface, HTTP 200 with substantive bodies each time. The same two strings with semaglutide in place of KPV returned 5,178 and 317 on 3 August 2026, which is how a live field and filter are told from a silently broken one. PubMed, KPV in title and abstract, PubMed, the same with the clinical-trial publication type, the semaglutide control, the semaglutide control with the same filter. ClinicalTrials.gov version 2 API, "query.term=KPV" and "query.intr=KPV" each return totalCount 0 with an empty study list, HTTP 200 with a substantive JSON body, on the same two dates; the semaglutide controls returned 757 and 730 on 3 August 2026. ClinicalTrials.gov, KPV as a search term, ClinicalTrials.gov, KPV as an intervention, the semaglutide term control, the semaglutide intervention control. Eight links for eight runs. A zero is a claim about a literature, so the query that produced it belongs in the source list beside the papers.

13. 13

    Pawar K. Microneedles Assisted Iontophoretic Transdermal Delivery of Drugs. Dissertation, Department of Pharmacal Sciences, Auburn University, handle 10415/3870. Its title page is dated 14 December 2013 and the Auburn repository record carries 1 November 2013; the two are separate dates and this entry does not treat the second as the document's own. Source of the time window under the enhancement ratios. Its Table 6.2 prints a microneedle-only total flux of 4.42 micrograms per square centimeter per hour and, on the definition given in its data-analysis section, divides each iontophoresis flux by that figure: 8.29 and 34.10 for the 0 to 6 hour period while the current ran, 0.65 and 1.42 for the 6 to 26 hour period after it stopped, and 4.47 and 17.76 for the column headed total flux, which that section defines as the plain average of the two phase fluxes rather than a duration-weighted figure. Table 6.3 repeats all three pairs in the 6 hour row of its current-duration series. The 2017 journal abstract in reference 4 reports 8-fold and 35-fold against microneedles alone without stating which window they belong to. Retrieved 3 August 2026, HTTP 200, 1,988,938-byte PDF. Auburn University electronic theses and dissertations, handle 10415/3870.

14. 14

    Saleeby Y, Gregory B. Amlexanox: A Promising Alternative to Steroid and Antihistamine Dependence in Patients with Mast Cell Activation Syndrome, Allergies, Asthma, and Autoimmunity - A Case Report Collection. J Indep Med. 2025;1(1):71-78. doi:10.71189/jim/2025/v01n01a06. A clinician case report collection whose subject is amlexanox, not a study of KPV and not an interventional trial of anything. It is the weakest source in this list and is cited for one thing only: the sentence in its third case reading "One notable adverse reaction following a dose of oral lysine-proline-valine", and the reaction described immediately after it. The report gives no amount, no date and no indication of which form was taken, sources its case data to an electronic health record, and records the same patient as managing 81 different medications and supplements in December 2023, so it supports a temporal association and nothing stronger. It is indexed in neither PubMed nor Europe PMC: searching both for this DOI returned zero results on 3 August 2026 while the same searches for reference 4's DOI each returned one, which is why the queries in reference 12 cannot see it. Retrieved 3 August 2026: the DOI resolved HTTP 200 to a 146,810-byte journal page, and the journal's article PDF returned HTTP 200, 675,413 bytes, a valid 8-page document.

15. 15

    Cheng J, Wu P, Li C, et al. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Sci Adv. 2026;12(3):eaea2989. doi:10.1126/sciadv.aea2989. PMID 41533788. Source of the only animal time course this page reports for plain KPV. The paper's subject is a self-immolative conjugate; plain KPV is its comparator, and both arms are followed as a Cy5 dye rather than assayed as peptide. In its biodistribution work, colitis mice received a single oral administration of free Cy5-KPV or of the conjugate, and the free peptide's colonic fluorescence diminished substantially by 12 hours and became negligible by 24, while the paper's own pharmacokinetic analysis puts the conjugate's colonic fluorescence area under the curve 3.8-fold above it. In the lipopolysaccharide-induced acute lung injury model, intravenous Cy5-KPV produced a rapid rise in plasma fluorescence that declined sharply to baseline within 4 hours. Nothing here is form-resolved data for KPV free base or KPV acetate, and nothing here is human. Retrieved 3 August 2026: the publisher's DOI landing ended at an HTTP 403 firewall challenge and is not counted as a resolution, so identity and text were taken from Crossref, HTTP 200, 16,110 bytes, PubMed EFetch, HTTP 200, 37,632 bytes, and the Europe PMC full text, HTTP 200, 221,092 bytes.